jRCT2071250008招募中不适用
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Amgen K.K.
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Participant has provided informed consent prior to initiation of any study specific activities/procedures.
- •Age >= 18 years (or legal adult age within country, whichever is older) at the time of signing the informed consent.
- •Histologically or cytologically confirmed SCLC with demonstrated progression or relapse.
- •Participants who progressed or recurred following 1 platinum-based regimen.
- •Measurable disease as defined per RECIST 1.1 within the 21-day screening period.
- •Eastern Cooperative Oncology Group (ECOG) PS of 0 or
- •Minimum life expectancy of 12 weeks.
- •Adequate organ function as described per protocol.
排除标准
- •Disease Related
- •Previous diagnosis of transformed non-small cell lung cancer (NSCLC) including epidermal growth factor receptor activating mutation positive NSCLC that has transformed to SCLC.
- •Symptomatic central nervous system (CNS) metastases with exceptions defined in the protocol.
- •Other Medical Conditions
- •History of other malignancy within the past 2 years, with exceptions defined in the protocol.
- •Evidence of interstitial lung disease or active, non-infectious pneumonitis
- •Diagnosis or evidence of leptomeningeal disease.
- •Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study.
- •7.History of solid organ transplantation.
- •Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association > class II) within 6 months prior to first dose of study treatment.
- •History of arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months prior to first dose of study treatment
- •Presence or history of viral infection based on criteria per protocol.
- •Symptoms and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection requiring antibiotics within 7days prior to the first dose study treatment.
- •Subject has known active infection requiring parenteral antibiotic treatment.
- •History of severe or life-threatening events from any immune-mediated therapy.
- •Major surgical procedures within 21 days of prior to first dose of study treatment.
- •Prior/Concomitant Therapy
- •Prior anticancer therapy within 30 days of enrollment (14 days for conventional chemotherapy).
- •Prior enrollment on a tarlatamab clinical trial OR prior therapy with any selective inhibitor of the DLL3 pathway.
- •Current anti-cancer therapy such as chemotherapy, immunotherapy, or targeted therapy with exceptions.
- •Receiving systemic corticosteroid therapy or any other immunosuppressive therapy within 7 days prior to first dose as described per protocol.
- •Live and live-attenuated vaccines within 14 days prior to the start of study treatment. Inactive vaccines and live viral non-replicating vaccines within 3 days prior to the first dose of study treatment.
- •Prior/Concurrent Clinical Study Experience
- •Currently receiving treatment in another investigational device or drug study, or less than 30 days or 5 half-lives since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
- •Other Exclusions
- •Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of tarlatamab.
- •Female participants who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of tarlatamab.
- •Female participants planning to become pregnant or donate eggs while on study through 60 days after the last dose of tarlatamab.
- •Female participants of childbearing potential with a positive pregnancy test assessed at screening and/or day 1 by a highly sensitiveurine or serum pregnancy test.
- •Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 60 days after the last dose of tarlatamab.
- •Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of tarlatamab.
- •Male participants unwilling to abstain from donating sperm during treatment and for an additional 60 days after the last dose of tarlatamab.
- •Participant has known sensitivity or is contraindicated to any of the products or components to be administered during dosing.
- •Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures.
- •History or evidence of any other clinically significant disorder, condition or disease determined by the investigator or Amgen physician, if consulted, would pose a risk to the subject safety or interfere with the study evaluation procedure or completion
研究者
相似试验
进行中（未招募）
1 期
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma (CTCL)EUCTR2011-001076-18-PTJanssen-Cilag International NV46
进行中（未招募）
1 期
A Study of the Histone Deacetylase Inhibitor (HDACi) JNJ-26481585 in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma (CTCL)Stage Ib-IVa Cutaneous T-cell LymphomaMedDRA version: 14.0Level: LLTClassification code 10011677Term: Cutaneous T-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001076-18-ESJanssen-Cilag International NV46
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesEUCTR2020-004175-41-ITeoImmuneTech, Inc.127
进行中（未招募）
1 期
A Multicenter, Open-label, Randomized, Phase 2 Study of NT-I7 in Combination with Nivolumab versus Nivolumab Alone in Subjects with Advanced or Metastatic Stomach, Esophageal Cancers who Progressed on or Were Intolerant to 2 or More Previous TherapiesAdvanced or metastatic gastric or gastro-esophageal junction (GEJ) or esophageal adenocarcinoma (EAC) progressed on or intolerant to 2 or more prior lines of systemic therapyMedDRA version: 21.0Level: LLTClassification code 10058526Term: Oesophageal adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: LLTClassification code 10082464Term: Advanced gastric carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.1Level: LLTClassification code 10084873Term: Gastrooesophageal junction cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10079913Term: Adenocarcinoma of the gastroesophageal junction stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10030145Term: Oesophageal adenocarcinoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004175-41-ESeoImmuneTech, Inc.127
进行中（未招募）
1 期
I-DXd in Patients With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)MedDRA version: 21.1Level: PTClassification code: 10041068Term: Small cell lung cancer extensive stage Class: 100000004864CTIS2024-512368-79-00Daiichi Sankyo Inc.191